Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Pharmaceuticals, Inc. (RCKT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, late-stage biotechnology company, Rocket uses SEC reports to communicate material information about its gene therapy pipeline, financial condition, governance and significant corporate events.
Investors can use this page to locate current reports on Form 8-K, which Rocket files to describe events such as financial results, strategic corporate reorganization and pipeline prioritization, clinical trial developments and regulatory milestones. Recent 8-K filings referenced in available information include announcements of quarterly financial results, FDA acceptance of the resubmitted Biologics License Application (BLA) for KRESLADI in severe leukocyte adhesion deficiency-I (LAD-I), lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease, and leadership or board changes.
In addition to 8-Ks, users can access Rocket’s periodic reports on Forms 10-K and 10-Q, which provide more detailed discussions of its AAV and lentiviral gene therapy programs, risk factors and financial statements. These filings help explain how Rocket is prioritizing its AAV cardiovascular platform—covering Danon disease, PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy—while advancing regulatory activities for KRESLADI and pausing additional internal investment in certain other programs.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as clinical and regulatory updates, restructuring plans, and changes in executive leadership. Real-time EDGAR updates allow users to see new Rocket filings as they are posted, while Form 4 insider transaction data and proxy materials can be reviewed to understand equity awards, inducement grants and governance practices. This page serves as a focused entry point for analyzing how Rocket’s SEC disclosures relate to the development and potential commercialization of its rare disease gene therapy portfolio.
Rocket Pharmaceuticals reported fourth-quarter 2025 net loss of $42,538, improving from $60,327 a year earlier. Full-year 2025 net loss was $223,123, compared with $258,746 in 2024, with net loss per share of $2.01 versus $2.73.
Total operating expenses for 2025 were $231,747, down from $273,205 in 2024, reflecting lower research and development and general and administrative spending and recorded restructuring charges of $3,231. Cash, cash equivalents and investments were $188,929 at December 31, 2025, versus $372,336 a year earlier, which the company says supports an operational runway into the second quarter of 2027.
Operationally, Rocket highlighted progress across its cardiovascular gene therapy programs. The pivotal Phase 2 trial of RP‑A501 for Danon disease is expected to resume in the first half of 2026, the KRESLADI™ BLA for severe LAD‑I has a March 28, 2026 PDUFA date, and first dosing in a Phase 1 study of RP‑A701 for BAG3‑related dilated cardiomyopathy is anticipated in mid‑2026.
Rocket Pharmaceuticals is a late-stage biotech company developing gene therapies for rare, often fatal genetic diseases, with a strategic focus on inherited cardiomyopathies. It runs both AAV and lentiviral platforms and operates a large cGMP manufacturing facility in Cranbury, New Jersey.
In 2025 Rocket implemented a corporate reorganization, including a workforce reduction of about 30% and cost-saving initiatives expected to lower 12‑month operating expenses by roughly 25%, to extend its cash runway and concentrate resources on its AAV cardiovascular pipeline. Development of Fanconi anemia and pyruvate kinase deficiency programs is being de‑prioritized while the company explores partnerships.
Lead programs include RP‑A501 for Danon disease, where positive long‑term Phase 1 data supported a pivotal Phase 2 trial that was temporarily paused after two serious adverse events, including one death, then allowed to resume at a lower dose with added safeguards. RP‑A601 for PKP2‑related arrhythmogenic cardiomyopathy has early Phase 1 data showing tolerability and increased PKP2 expression, and RP‑A701 for BAG3‑related dilated cardiomyopathy entered Phase 1 after FDA IND clearance and Fast Track designation.
In hematology, ex vivo gene therapy KRESLADI for severe LAD‑I has published long‑term data and a resubmitted BLA with a new PDUFA date of March 28, 2026. Across programs, Rocket highlights extensive regulatory designations, complex licensing arrangements, and a wide array of risks, including ongoing losses, financing needs, clinical and regulatory uncertainty, manufacturing and data‑privacy obligations, intense competition, and protection of its intellectual property.
Rocket Pharmaceuticals, Inc. officer John Militello reported an open-market sale of 1,157 shares of common stock at an average price of $3.338 per share. According to the filing, the shares were sold to cover tax withholding obligations from vesting restricted stock units, and he now holds 91,019 shares, including RSUs that convert one-for-one into common stock.
Rocket Pharmaceuticals CEO Gaurav Shah reported a tax-related stock sale. On February 18, 2026, he sold 5,990 shares of common stock at $3.338 per share to cover tax withholding obligations tied to vesting restricted stock units. After this transaction, he directly holds 1,046,055 common shares, with additional indirect holdings of 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.
Rocket Pharmaceuticals General Counsel Wilson Martin reported an open-market sale of company stock. On February 18, 2026, he sold 1,376 shares of Common Stock at an average price of $3.338 per share in a transaction classified as an open-market sale.
According to the footnotes, the shares were sold to pay tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). After this sale, Martin beneficially owned 682,000 shares, which include RSUs that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. General Counsel Wilson Martin sold 12,253 shares of common stock on February 13, 2026 in an open-market transaction at an average price of $3.312 per share. According to the disclosure, the sale was made to pay tax withholding obligations tied to the vesting of restricted stock units (RSUs). After this transaction, Martin directly owned 683,376 shares, and his holdings include RSUs that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals officer John Militello reported an open-market sale of 3,726 shares of common stock at $3.312 per share. According to the footnotes, the sale was made to cover tax withholding obligations from vested restricted stock units, and Militello now holds 92,176 shares, including RSUs that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah sold 12,279 shares of common stock at $3.312 per share on February 13, 2026 in an open-market transaction. According to the footnotes, the sale was made to cover tax withholding obligations tied to vesting restricted stock units that convert one-for-one into common shares. After this sale, Shah directly holds 1,052,045 shares, and also reports indirect holdings of 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.
Rocket Companies insider sale notice: a Form 144 lists 1,157 common shares related to restricted stock vesting dated 02/13/2026.
The filing also records prior sales by John Militello: 1,086 shares on 11/18/2025 and 3,726 shares on 02/13/2026.
RCKT filing of a Form 144 reports proposed sale of 1,376 common shares tied to restricted stock vesting dated 02/13/2026. The filing also records prior sales by the reporting person: 1,646 shares on 11/18/2025 and 12,253 shares on 02/13/2026.